How Peptide-Based Imaging and Therapy Are Transforming Neuroendocrine Tumor Treatment | Research

The takeaway

Somatostatin analog peptides now serve as both diagnostic imaging agents and targeted radiation therapy for neuroendocrine tumors, with next-generation approaches promising even better results.

FDA/EMA approved
177Lu-DOTATATE peptide therapy is now part of standard treatment guidelines for somatostatin receptor-positive neuroendocrine tumors

What the researchers found

Peptide receptor radionuclide therapy (PRRT) using somatostatin analogs labeled with lutetium-177 or yttrium-90 is now an established, FDA- and EMA-approved treatment for neuroendocrine tumors (NETs). The same peptides labeled with gallium-68 ([68Ga]-DOTA-peptides) serve as diagnostic imaging agents — making this a true theranostic approach where one peptide family both finds and treats cancer.

The review highlights emerging advances: personalized treatment schemes, SSTR antagonists (which may outperform current agonists), alpha-emitting radioisotopes for therapy, 18F-labeled somatostatin analogs for improved imaging, and combination strategies pairing PRRT with other treatments.

Why it matters

Peptide-based theranostics represent one of the most successful translations of peptide science into clinical medicine. Using the same somatostatin analog peptide to both image tumors with PET scans and then deliver targeted radiation therapy is a paradigm that other cancer types are trying to replicate. This review captures the current state of a field where peptides are genuinely saving lives.

The numbers in context

PRRT in use since mid-1990s · 177Lu-DOTATATE FDA/EMA approved · 3 main 68Ga-DOTA-peptides for imaging · tumors originate mostly from GI tract and lungs · SSTR expression determines eligibility

How the study worked

Narrative review covering the current knowledge base and emerging perspectives for molecular imaging and therapy of neuroendocrine tumors. Covers established somatostatin receptor-targeting peptides, PRRT clinical evidence, and next-generation radiopharmaceuticals under development.

Who was studied

Review covering patients with neuroendocrine tumors (NETs)

What this study cannot tell us

As a narrative review, this does not perform a systematic analysis of all available evidence. The emerging strategies discussed (SSTR antagonists, alpha-labeling, 18F-labeled peptides) are still largely in early clinical or preclinical stages. The review focuses primarily on well-differentiated NETs that express somatostatin receptors, which excludes poorly differentiated neuroendocrine carcinomas.

How to read the evidence

This is a strong-evidence review published in a leading nuclear medicine journal. It synthesizes established clinical evidence including FDA/EMA-approved therapies backed by phase III trial data.

When this study was published

Published in 2023, this review captures the state of the field after FDA/EMA approval of 177Lu-DOTATATE and during active development of next-generation peptide radiopharmaceuticals.

The bigger picture

Peptide-based theranostics for NETs is arguably the greatest success story in peptide medicine. The concept — use the same targeting peptide for diagnosis and treatment — has inspired similar approaches in prostate cancer (PSMA-targeting) and other cancers. This review documents a field that has matured from experimental to standard-of-care while still innovating rapidly.

Questions still open

Will SSTR antagonists prove superior to current agonist-based PRRT in clinical trials?
Can alpha-emitting radioisotopes overcome resistance to current beta-emitting PRRT?
How should PRRT be optimally sequenced with other treatments like chemotherapy and targeted therapy?

Common questions

What does 'theranostic' mean in the context of peptide medicine?

Theranostics combines therapy and diagnostics into one approach. For neuroendocrine tumors, the same somatostatin analog peptide is used twice: first labeled with gallium-68 to create a PET scan image showing where tumors are located, then labeled with lutetium-177 to deliver targeted radiation directly to those same tumors. One peptide, two jobs.

What are neuroendocrine tumors and why are they suited to peptide therapy?

Neuroendocrine tumors (NETs) are rare cancers that arise from hormone-producing cells, most commonly in the digestive tract and lungs. Many NETs display high levels of somatostatin receptors on their surface, making them ideal targets for somatostatin analog peptides that can deliver radioactive payloads directly to tumor cells while largely sparing healthy tissue.

Read the original research

Molecular imaging Theranostics of Neuroendocrine Tumors.

Seminars in nuclear medicine, 53(4), 539-554

View on PubMed ↗Publisher’s paper ↗

Citation

Fortunati, Emilia; Bonazzi, Norma; Zanoni, Lucia; Fanti, Stefano; Ambrosini, Valentina. (2023). Molecular imaging Theranostics of Neuroendocrine Tumors.. Seminars in nuclear medicine, 53(4), 539-554. https://doi.org/10.1053/j.semnuclmed.2022.12.007